News | June 08, 2015

Mevion Medical Systems First to Open Back-to-Back Proton Therapy Centers

New Jersey’s Robert Wood Johnson University Hospital treats first patients with the Mevion S250 system weeks after Ackerman Cancer Center in Florida

Mevion, S250, Robert Wood Johnson University Hospital, back-to-back, proton

June 8, 2015 - The Mevion S250 proton therapy system at Robert Wood Johnson University Hospital (RWJUH) is now treating patients, less than four weeks after the first Mevion patient was treated at Ackerman Cancer Center. The occasion marks the first time a proton manufacturer has simultaneously brought up two distinct facilities.

The first two patients treated at RWJUH included a young man with a spinal myxopapillary ependymoma, a cancer that affects the spinal canal. His treatment began on June 5. A second patient with a recurrent brain tumor began treatment on May 27; this patient had received full doses of radiation in the past, and re-treating him with other technologies would have proved difficult. RWJUH, in New Brunswick, New Jersey, is the flagship Cancer Hospital of Rutgers Cancer Institute of New Jersey and the principal teaching hospital of Rutgers Robert Wood Johnson Medical School.

Proton therapy provides targeted treatment to cancer cells and causes less damage to surrounding healthy tissues than photon radiation. This makes it an ideal option for pediatric and adult patients with tumors in sensitive locations, such as near the heart, brain and spine.

Traditionally, proton therapy systems have required the development of new football-field-sized facilities that have ended up costing hundreds of millions of dollars to build and operate. Because only a limited number of cancer centers have this kind of capital or space, there has been a lack of patient access to this important treatment modality. The Mevion S250 is the world's smallest single-room proton therapy system and can be readily integrated into any size cancer facility – existing or new. The result is a proton therapy solution that is 75 percent smaller and uses as much as 90 percent less energy, resulting in significantly lower capital and operating costs.

"The MEVION S250 provides RWJUH with a compact, high-quality delivery system to include in our suite of patient treatment options," said Bruce Haffty, M.D., chief of radiation oncology at RWJUH and professor and chairman of the Department of Radiation Oncology at the Cancer Institute of New Jersey, Robert Wood Johnson Medical School and New Jersey Medical School at Rutgers University. "This is an important milestone in cancer therapy for patients in this region. We can now treat patients in less time with fewer side effects with a very targeted form of radiation therapy."

RWJUH is fully accredited by the American College of Surgeons Commission on Cancer.

"We always strive for excellence in cancer treatment," said Atif Khan, M.D., a radiation oncologist at Rutgers Cancer Institute of New Jersey and associate professor of radiation oncology at Rutgers Robert Wood Johnson Medical School. "I am excited to see the benefits that the Mevion S250 brings to the patients at our proton center."

The S250 began treating patients at Ackerman Cancer Center - a physician-owned facility in Jacksonville, Florida - on April 30 and is currently treating 24 patients per day. Mevion S250 systems are currently being installed at four additional sites in the United States, including University Hospitals Health System in Cleveland, where the superconducting synchrocyclotron accelerator is scheduled to be delivered at the end of June. Other installation sites are: Stephenson Cancer Center at the University of Oklahoma in Oklahoma City; University of Florida Health Cancer Center at Orlando Health; and MedStar Georgetown University Hospital's Lombardi Comprehensive Cancer Center in Washington, D.C.

For more information: www.mevion.com

Related Content

RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Provision Healthcare Joins RayCare Clinical Partners
News | Oncology Information Management Systems (OIMS) | September 11, 2017
Provision, located in Knoxville, Tenn., is the latest to partner with RaySearch Laboratories on the development of its...
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Sponsored Content | Videos | Radiation Therapy | September 08, 2017
The new Visicoil MR is a helically-wound, flexible linear fiducial marker.
The IBA Proteus Plus

The IBA Proteus Plus.

Feature | Proton Therapy | September 08, 2017 | By Jeff Zagoudis
As one of the more precise methods of delivering radiation therapy for cancer treatment, proton therapy has grown at a...
Overlay Init